Initial studies indicate that targeting peroxisomes could mitigate cognitive impairment and neurodegeneration in AD models, highlighting the potential of ACBD5 as a therapeutic target for Alzheimer’s disease. Here, ACBD5 is linked to early-onset autosomal dominant Alzheimer disease.